{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-391952","form_type":"8-K","ticker":"PBLS","cik":"0001657677","company_name":"Parabilis Medicines, Inc.","filed_at":"2026-09-15T20:15:35+00:00","discovered_at":"2026-09-15T20:17:05.436136+00:00","generated_at":"2026-09-15T20:17:12.627883+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Parabilis to present updated zolucatetide data in desmoid tumors at ESMO 2026","bullets":["Updated Phase 1/2 zolucatetide data in desmoid tumors to be presented at ESMO Congress 2026 in Madrid.","Oral presentation scheduled Oct 24, 2:45pm CEST in sarcoma-focused Proffered Paper session.","Company updates guidance to reflect intention to present data; no numbers disclosed yet."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-391952","json":"https://secwatch.observer/filing/0001193125-26-391952.json","markdown":"https://secwatch.observer/filing/0001193125-26-391952.md","text":"https://secwatch.observer/filing/0001193125-26-391952.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1657677/000119312526391952/0001193125-26-391952-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1657677/000119312526391952/ck0001657677-20260915.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-15T20:17:12.627883+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}